OncoMatch/Clinical Trials/NCT06637163
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
Is NCT06637163 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy and Paclitaxel + Carboplatin + Radiotherapy for esophageal squamous cell carcinoma.
Treatment: Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy · Paclitaxel + Carboplatin + Radiotherapy — This study will explore the efficacy and safety of benmelstobart combined with radiochemotherapy compared to radiochemotherapy alone as neoadjuvant treatment for esophageal squamous cell carcinoma. It will also compare the effectiveness and safety of low-dose radiotherapy versus standard-dose radiotherapy in neoadjuvant regimens that include benmelstobart with concurrent radiochemotherapy. This research may provide more treatment options for patients with esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage T1-3N+M0, T3NANYM0
clinical stages T1-3N+M0 or T3NanyM0 of resectable esophageal squamous cell carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
No prior antitumor treatment for esophageal cancer, including chemotherapy, hormone therapy, radiotherapy, or immunotherapy.
Cannot have received: hormone therapy
No prior antitumor treatment for esophageal cancer, including chemotherapy, hormone therapy, radiotherapy, or immunotherapy.
Cannot have received: radiotherapy
No prior antitumor treatment for esophageal cancer, including chemotherapy, hormone therapy, radiotherapy, or immunotherapy.
Cannot have received: immunotherapy
No prior antitumor treatment for esophageal cancer, including chemotherapy, hormone therapy, radiotherapy, or immunotherapy.
Lab requirements
Blood counts
Hb ≥ 90 g/L (no blood transfusion in last 14 days); neutrophil count ≥ 1.5 × 10^9/L; platelet count ≥ 100 × 10^9/L; WBC ≥ 3 × 10^9/L
Kidney function
serum creatinine ≤ 1.5 × ULN (or creatinine clearance ≥ 60 mL/min)
Liver function
ALT and AST ≤ 2.5 × ULN; total bilirubin ≤ 1.5 × ULN
Cardiac function
LVEF ≥ 50%
Laboratory tests must meet the following criteria ... Complete blood count ... Biochemical tests ... Coagulation function ... Thyroid function ... Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify